eFFECTOR drops MNK inhibitor after lung cancer flop

2024-04-04

临床结果临床2期抗体药物偶联物临床1期

eFFECTOR Therapeutics said Thursday it will halt development of tomivosertib in lung cancer after the MNK inhibitor failed to significantly improve survival. Shares of the selective translation regulator inhibitor (STRI) developer plummeted 82%.

The 180-person Phase II KICKSTART trial randomised patients with PD-L1-expressing non-small-cell lung cancer (NSCLC)PD-L1-expressing non-small-cell lung cancer (NSCLC) to receive either tomivosertib plus Merck & Co.’s Keytruda (pembrolizumab) as a frontline treatment, or the anti-PD-1 antibody plus placebo.

The tomivosertib arm achieved a median progression free survival (PFS) of 13 weeks, which was not statistically significant compared with the PFS of 11.7 weeks seen by the comparator arm.

Additionally, eFFECTOR said that there is “no trend favouring tomivosertib” in regards to overall survival (OS). The oral small molecule also had a worse safety profile, with 67% Grade 3 or higher treatment emergent adverse events compared with 37% in the Keytruda plus placebo group.

While chief executive Steve Worland confirmed that “tomivosertib won’t be moving forward in frontline NSCLC,” he added that an investigator-sponsored trial in acute myeloid leukaemia (AML) “will continue unchanged.”

Moving forward, eFFECTOR will be focusing its development efforts on zotatifin, a small molecule inhibitor of eIF4A that’s in Phase II testing to treat ER-positive breast cancer and KRAS-mutant NSCLC in combination with Faslodex (fulvestrant) and Verzenio (abemaciclib). A data readout is expected next half.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

eFFECTOR Therapeutics, Inc.